SCHEMBL2820533

SCHEMBL2820533

Cc1nc2cc(F)c(F)cc2c(OC(=O)C2CC2)c1C

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
RAB9A P51151 1/20 0.34
CYP11B2 P19099 4/20 0.32
ALDH1A1 P00352 4/20 0.32
CYP11B1 P15538 2/20 0.32
HPGD P15428 3/20 0.32
KDM4E B2RXH2 3/20 0.32
SMN1; SMN2 Q16637 3/20 0.32
LMNA P02545 2/20 0.32
CASP1 P29466 1/20 0.31
HSD17B10 Q99714 1/20 0.31
MAPT P10636 1/20 0.31
HRH3 Q9Y5N1 1/20 0.31
GRM1 Q13255 3/20 0.31
HTT P42858 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
TOP2A P11388 1/20 0.30
TOP2B Q02880 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2821034 0.90 PTGS2 (0.33) L3MBTL1KMT2AMEN1RAB9AHPGD
SCHEMBL2823237 0.88 KDR (0.31) L3MBTL1KMT2AMEN1RAB9AALDH1A1
SCHEMBL2822997 0.85 L3MBTL1 (0.33) L3MBTL1KMT2AMEN1RAB9ACYP11B2
SCHEMBL2819937 0.85 USP2 (0.38) L3MBTL1KMT2AMEN1RAB9ACYP11B2
SCHEMBL2825212 0.84 HPGD (0.34) L3MBTL1KMT2AMEN1RAB9AALDH1A1
SCHEMBL2819557 0.82 HTT (0.35) KMT2AMEN1ALDH1A1HPGDKDM4E
SCHEMBL2823000 0.81 USP2 (0.37) L3MBTL1KMT2AMEN1RAB9ACYP11B2
SCHEMBL2823211 0.79 LMNA (0.38) ALDH1A1HPGDKDM4ESMN1; SMN2LMNA
SCHEMBL2823212 0.77 SCN9A (0.34) KMT2AMEN1HPGDKDM4ESMN1; SMN2
SCHEMBL2823045 0.77 KMT2A (0.33) L3MBTL1KMT2AMEN1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1386914-B1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA (JP) 2010-10-27 EP disclosed
US-7022855-B2 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2006-04-04 US disclosed
EP-1559321-A1 MIXED COMPOSITIONS FOR CONTROLLING PARASITIC INSECTS MEIJI SEIKA KAISHA LTD. (JP) 2005-08-03 EP disclosed
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent MEIJI SEIKA KAISHA, LTD. (JP) 2004-05-06 US disclosed
US-20040077602-A1 Mixture composition for controlling ectoparasites MEIJI SEIKA KAISHA, LTD. (JP) 2004-04-22 US disclosed
EP-1386914-A1 HALOGENATED QUINOLINE DERIVATIVES AND ECTOPARASITE CONTROLLERS MEIJI SEIKA KAISHA LTD. (JP) 2004-02-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040087618-A1 Halogen-substituted quinoline derivatives and ectoparasite control agent ATL3, RABL3, RAB5C L3MBTL1 130/4885KMT2A 1368/4885MEN1 3131/4885
US-20040077602-A1 Mixture composition for controlling ectoparasites SF3A3, PEX3, HCN3 L3MBTL1 156/4885KMT2A 1494/4885MEN1 2772/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.